Literature DB >> 17767599

Inflammation of paranasal sinuses: the clinical pattern is age-dependent.

G L Marseglia1, A M Castellazzi, A Licari, A Marseglia, M Leone, F Pagella, G Ciprandi, C Klersy.   

Abstract

Acute rhinosinusitis (ARS) represents a common disorder, associated with consistent morbidity as well as with a large prescription of antibiotics. ARS has a significant impact on clinical practice; it usually presents with respiratory complaints persisting longer than 10 days and showing no signs of improvement. Throughout the evaluation of 256 pediatric patients (152 males and 135 females, aged between 2 and 15 yr), with ARS confirmed by nasal endoscopy, we have been able to provide evidence that age has a significant influence on clinical patterns in children with ARS.

Entities:  

Mesh:

Year:  2007        PMID: 17767599     DOI: 10.1111/j.1399-3038.2007.00624.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  3 in total

1.  Predisposing factors associated with chronic and recurrent rhinosinusitis in childhood.

Authors:  Sun-Hee Choi; Man-Yong Han; Young-Min Ahn; Yong-Mean Park; Chang-Keun Kim; Hyun-Hee Kim; Young-Yull Koh; Yeong-Ho Rha
Journal:  Allergy Asthma Immunol Res       Date:  2011-11-15       Impact factor: 5.764

Review 2.  Novel therapeutic targets for allergic airway disease in children.

Authors:  Alessandro Giallongo; Giuseppe Fabio Parisi; Amelia Licari; Giulio Pulvirenti; Caterina Cuppari; Carmelo Salpietro; Gian Luigi Marseglia; Salvatore Leonardi
Journal:  Drugs Context       Date:  2019-07-09

3.  Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray for treatment of upper respiratory tract infections in children: a pilot study on short-term efficacy.

Authors:  Sara Manti; Giuseppe Fabio Parisi; Maria Papale; Amelia Licari; Carmelo Salpietro; Michele Miraglia Del Giudice; Gian Luigi Marseglia; Salvatore Leonardi
Journal:  Ital J Pediatr       Date:  2020-04-03       Impact factor: 2.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.